Your browser doesn't support javascript.
loading
Role of Sleep Apnea and Long-Term CPAP Treatment in the Prognosis of Patients With Melanoma: A Prospective Multicenter Study of 443 Patients.
Gómez-Olivas, Jose Daniel; Campos-Rodriguez, Francisco; Nagore, Eduardo; Martorell, Antonio; García-Rio, Francisco; Cubillos, Carolina; Hernandez, Luis; Bañuls, Jose; Arias, Eva; Ortiz, Pablo; Cabriada, Valentin; Gardeazabal, Juan; Montserrat, Josep Maria; Carrera, Cristina; Masa, Juan Fernando; Gomez de Terreros, Javier; Abad, Jorge; Boada, Adam; Mediano, Olga; Castillo-Garcia, Marta; Chiner, Eusebi; Landete, Pedro; Mayos, Mercedes; Fortuna, Ana; Barbé, Ferrán; Sanchez-de-la-Torre, Manuel; Cano-Pumarega, Irene; Perez-Gil, Amalia; Gomez-Garcia, Teresa; Cullen, Daniela; Somoza, Maria; Formigon, Manuel; Aizpuru, Felipe; Oscullo, Grace; Garcia-Ortega, Alberto; Almendros, Isaac; Farré, Ramón; Gozal, David; Martinez-Garcia, Miguel Angel.
Afiliação
  • Gómez-Olivas JD; Respiratory Department, Hospital Universitario y Politecnico la Fe, Hospital de Manises, Valencia, Spain.
  • Campos-Rodriguez F; Respiratory Department, Instituto Andaluz de Investigación, Seville, Spain; Hospital Valme, IBIS, Instituto Andaluz de Investigación, Seville, Spain; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain.
  • Nagore E; Dermatology Department, Instituto Valenciano de Oncologia, Hospital de Manises, Valencia, Spain.
  • Martorell A; Dermatology Department, Hospital de Manises, Valencia, Spain.
  • García-Rio F; Respiratory Department, Hospital Universitario La Paz, IdiPaz, Spain; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain.
  • Cubillos C; Respiratory Department, Hospital Universitario La Paz, IdiPaz, Spain; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain.
  • Hernandez L; Respiratory Department, Hospital General Universitario Balmis de Alicante, UMH, Spain; Clinical Medicine Department, UMH, Spain.
  • Bañuls J; Dermatology Department, Hospital General Universitario Balmis de Alicante, UMH, Spain; Clinical Medicine Department, UMH, Spain.
  • Arias E; Respiratory Department, Hospital Universitario 12 de Octubre, Spain.
  • Ortiz P; Dermatology Department, Hospital Universitario 12 de Octubre, Spain.
  • Cabriada V; Respiratory Department, Hospital Universitario Cruces, Barakaldo, Spain.
  • Gardeazabal J; Dermatology Department, Hospital Universitario Cruces, Barakaldo, Spain.
  • Montserrat JM; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Clinic-IDIBAPS, Spain.
  • Carrera C; Dermatology Department, Hospital Clinic-IDIBAPS, Spain.
  • Masa JF; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Universitario San Pedro de Alcantara, Caceres, Spain.
  • Gomez de Terreros J; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Universitario San Pedro de Alcantara, Caceres, Spain.
  • Abad J; Respiratory Department, Hospital Universitario Germans Trials I Pujol, Spain.
  • Boada A; Dermatology Department, Hospital Universitario Germans Trials I Pujol, Spain.
  • Mediano O; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Universitario General de Guadalajara, Guadalajara, Spain.
  • Castillo-Garcia M; Respiratory Department, Hospital Universitario General de Guadalajara, Guadalajara, Spain.
  • Chiner E; Respiratory Department, Hospital Universitario San Juan de Alicante, Alicante, Spain.
  • Landete P; Respiratory Department, Hospital Universitario San Juan de Alicante, Alicante, Spain.
  • Mayos M; Respiratory Department, Hospital Universitario Santa Creu i Sant Pau, Spain.
  • Fortuna A; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Respiratory Department, Hospital Universitario Santa Creu i Sant Pau, Spain.
  • Barbé F; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Group of Precision Medicine in Chronic Diseases, Respiratory Department, University Hospital Arnau de Vilanova and Santa María, Spain; Department of Nursing and Physiotherapy, Faculty of Nursing and Physiotherapy, University of Lleida. IR
  • Sanchez-de-la-Torre M; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Group of Precision Medicine in Chronic Diseases, Respiratory Department, University Hospital Arnau de Vilanova and Santa María, Spain; Department of Nursing and Physiotherapy, Faculty of Nursing and Physiotherapy, University of Lleida. IR
  • Cano-Pumarega I; Respiratory Department, Hospital Universitario Ramon y Cajal, IRYCIS, Spain.
  • Perez-Gil A; Dermatology Department, Instituto Andaluz de Investigación, Seville, Spain.
  • Gomez-Garcia T; Respiratory Department, Fundacion Jimenez Diaz, Madrid, Spain; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain.
  • Cullen D; Dermatology Department, Fundacion Jimenez Diaz, Madrid, Spain.
  • Somoza M; Respiratory Department, Consorcio Sanitario Terrassa, Spain.
  • Formigon M; Dermatology Department, Consorcio Sanitario Terrassa, Spain.
  • Aizpuru F; Biostatistical Service, BioAraba, Health Research Institute, OSI Araba University Hospital, Basque Health Service, University of the Basque Country, Leioa, Spain.
  • Oscullo G; Respiratory Department, Hospital Universitario y Politecnico la Fe, Hospital de Manises, Valencia, Spain.
  • Garcia-Ortega A; Respiratory Department, Hospital Universitario y Politecnico la Fe, Hospital de Manises, Valencia, Spain.
  • Almendros I; Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias, Madrid, Spain; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Unitat de Biofisica i Bioenginyeria, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions
  • Farré R; Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias, Madrid, Spain; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain; Unitat de Biofisica i Bioenginyeria, Facultat de Medicina i Ciencies de la Salut, Universitat de Barcelona, Barcelona, Spain; Institut d'Investigacions
  • Gozal D; Department of Child Health and Child Health Research Institute, School of Medicine, The University of Missouri, Columbia, MO.
  • Martinez-Garcia MA; Respiratory Department, Hospital Universitario y Politecnico la Fe, Hospital de Manises, Valencia, Spain; CIBERes, VCIBER de Enfermedades Respiratorias, Madrid, Spain. Electronic address: mianmartinezgarcia@gmail.com.
Chest ; 164(6): 1551-1559, 2023 12.
Article em En | MEDLINE | ID: mdl-37348828
ABSTRACT

BACKGROUND:

OSA has been associated with increased incidence and aggressiveness of melanoma. However, the long-term impact of OSA and CPAP treatment on the prognosis of melanoma remains unexplored. RESEARCH QUESTION Are OSA and CPAP treatment associated independently with a poor prognosis for cutaneous melanoma? STUDY DESIGN AND

METHODS:

Four hundred forty-three patients with a diagnosis of cutaneous melanoma (2012-2015) underwent a sleep study within 6 months of diagnosis. The main 5-year outcome of the study was a composite of melanoma recurrence, metastasis, or mortality. Patients were divided into four groups baseline apnea-hypopnea index (AHI) of fewer than 10 events/h (no OSA; control group), OSA treated with CPAP and good adherence, untreated or poor CPAP adherence in moderate (AHI, 10-29 events/h), and severe OSA (AHI, ≥ 30 events/h). Survival analysis was used to determine the independent role of OSA and CPAP treatment on melanoma composite outcome.

RESULTS:

Three hundred ninety-one patients (88.2%) were available for analysis at 5-year follow-up (mean age, 65.1 ± 15.2 years; 49% male; Breslow index, 1.7 ± 2.5 mm). One hundred thirty-nine patients had AHI of fewer than 10 events/h (control group); 78 patients with OSA were adherent to CPAP; and 124 and 50 patients had moderate and severe OSA, respectively, without CPAP treatment. Median follow-up was 60 months (interquartile range, 51-74 months). During follow-up, 32 relapses, 53 metastases, and 52 deaths occurred (116 patients showed at least one of the main composite outcomes). After adjusting for age, sex, sentinel lymph nodes affected at diagnosis, BMI, diabetes, nighttime with an oxygen saturation below 90%, Breslow index, Epworth sleepiness scale scores, and melanoma treatment, moderate (hazard ratio [HR], 2.45; 95% CI, 1.09-5.49) and severe OSA (HR, 2.96; 95% CI, 1.36-6.42) were associated with poorer prognosis of melanoma compared with the control group. However, good adherence to CPAP avoided this excess risk (HR, 1.66; 95% CI, 0.71-3.90).

INTERPRETATION:

Moderate to severe untreated OSA is an independent risk factor for poor prognosis of melanoma. Treatment with CPAP is associated with improved melanoma outcomes compared with untreated moderate to severe OSA.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Síndromes da Apneia do Sono / Apneia Obstrutiva do Sono / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Síndromes da Apneia do Sono / Apneia Obstrutiva do Sono / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Chest Ano de publicação: 2023 Tipo de documento: Article